New cancer drug IDE161 enters human testing
NCT ID NCT05787587
First seen Jun 24, 2026 · Last updated Jul 14, 2026 · Updated 4 times
Summary
This early-stage trial is testing a new drug called IDE161, alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The main goals are to check safety, find the right dose, and get a first look at whether it shrinks tumors. About 216 people will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IDE-161 (PARG inhibitor) and pembrolizumab (immunotherapy)
- What this could lead to
- If successful, this could point toward a new treatment option for certain advanced cancers, especially those with DNA repair deficiencies.
- What could go wrong
- This is an early Phase 1 trial, so safety and dosing are still being figured out. Many drugs fail at this stage, and benefits may be limited or not seen at all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
California Pacific Medical Center
San Francisco, California, 94115, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89169, United States
-
Dana Faber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Hoag Memorial Hospital
Newport Beach, California, 92663, United States
-
HonorHealth Research Institute
Phoenix, Arizona, 85027, United States
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
MD Anderson
Houston, Texas, 77030, United States
-
NEXT Oncology
Irving, Texas, 75039, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
NEXT Oncology
Fairfax, Virginia, 22031, United States
-
OSF St Francis Medical Center
Peoria, Illinois, 61637, United States
-
Orlando Health
Orlando, Florida, 32806, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14203, United States
-
START Mountain Region
West Valley City, Utah, 84119, United States
-
Sarah Cannon Research Institute
Denver, Colorado, 80218, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute - Oklahoma University
Oklahoma City, Oklahoma, 73104, United States
-
Sarah Cannon Research Institute - Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
Swedish Cancer Institute
Seattle, Washington, 98104, United States
-
The Angeles Clinic
Los Angeles, California, 90025, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
-
Weil Cornell University
New York, New York, 10065, United States
-
Yale University
New Haven, Connecticut, 06511, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a new tracer light up hidden prostate cancer?
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts